Cingulate Inc.

NASDAQ:CING

Biotechnology

Healthcare
$5.11 -0.95%

-$0.05 today

Market cap
$76.46M
Beta
-0.91
P/E (TTM)
-1.0
EPS (TTM)
-$5.10
52W Low $3.16High $11.89

Volume 0.95M

Average 0.46M

CING Total Debt

Short-term and long-term borrowings combined.

Cingulate Inc.NASDAQ: CING

Total Debt · Q1 FY2026 · quarter ended Mar 2026

Total debt rises 46.2% from a year ago

Total debt stood at $7.43M at the end of Q1 FY2026, up 46.2% from a year earlier and down 15.5% from the prior quarter. Over 3 fiscal years it compounded at +14.4% a year.

Context

  • Total debt amounted to 24.1% of total assets at the end of Q1 FY2026, down 16.7 pp from a year earlier.
  • Total debt increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether total debt keeps rising in the next quarterly balance sheet after a +46.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$7.43M-15.5% QoQ
Last fiscal yearDec 2025
$8.79M+72.3% YoY
Year agoMar 2025
$5.08M+46.2% since
Total Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+46.2%——
1 year+72.3%——
3-year CAGR+14.4%——
5-year CAGR——
10-year CAGR——

Total Debt history

USD · from the balance sheet

Latest · FY2025
8.79M USD
Year-over-year change
+72.3%
4-year CAGR
+64.8%

Total Debt vs competitors

How CING compares with its peers on the latest reported figures

  • CING's Mar 2026 total debt of $7.43M is the highest of the 2 companies compared; the peer median is $1.06M.
  • Total debt amounts to 24.1% of total assets for CING, versus a peer median of 9.7%.
CING Competitors Peer median
Total Debt for CING and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
CINGCingulate Inc.Mar 2026$7.43M +46.2%+14.4%24.1%
LIXTLixte Biotechnology Holdings, Inc.Mar 2026$1.06M ——9.7%
Peer median (excluding CING) $1.06M——9.7%

Competitors are the stored peer set for CING. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents16.49M5.36M52.42K12.21M10.95M
Short-term Investments9330000
Net Receivables690.25K234.43K14.62K26.33K8.01K
Inventory0100.34K000
Other Current Assets1.7M1.64M490.86K368.29K80.08K
Total Current Assets18.88M7.87M578.59K12.66M12.01M
Property, Plant & Equipment (Net)4M3.54M2.91M2.2M3.07M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets1.36B5.91B000
Other Non-current Assets(1.36B)(5.91B)000
Total Non-current Assets4M3.54M2.91M2.2M3.07M
Total Assets22.89M11.41M3.49M14.86M15.07M
Account Payables264.69K762.36K5.2M1.27M2.04M
Short-term Debt310.69K5M3M2.53M6.3M
Tax Payables00120.57K200K0
Deferred Revenue601.3K0000
Other Current Liabilities(336.67K)719.01K593.02K355.48K455.18K
Total Current Liabilities1.18M7.01M10.23M4.97M10.31M
Long-term Debt0002.44M1.15M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities866.04K510.24K135.1K2.44M2.25M
Total Liabilities2.04M7.52M10.36M7.41M12.56M
Common Stock1.13K6110340725
Retained Earnings(51.73M)(69.41M)(92.94M)(108.49M)(132.38M)
Accumulated OCI1650000
Other Stockholders Equity00000
Minority Interest00000
Total Equity20.84M3.88M(6.87M)7.46M2.51M
Total Debt1.19M5.87M3.51M5.1M8.79M
Net Debt(15.3M)509.77K3.46M(7.11M)(2.17M)

Cingulate Inc.

NASDAQ:CING

Intrinsic Alpha fair value

Locked

Current Price

$5.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.